Global Hepatitis B Infection Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2024 –2031 |
 Market Size (Base Year) |
USD 12.11 Billion |
 Market Size (Forecast Year) |
USD 18.21 Billion |
 CAGR |
% |
| Major Markets Players |
>全球乙型肝炎感染市场，按类型（急性、慢性）、治疗（抗病毒药物、疫苗、免疫调节药物、手术）、分销渠道（医院和零售药店、网上药店）国家（美国、加拿大、墨西哥、巴西、阿根廷、秘鲁、南美洲其他地区、德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、匈牙利、立陶宛、奥地利、爱尔兰、挪威、波兰、欧洲其他地区、中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、越南、亚太其他地区、沙特阿拉伯、阿联酋、埃及、以色列、科威特、南非、中东和非洲其他地区）行业趋势和预测到 2029 年。
市场分析与洞察全球乙型肝炎感染市场
乙肝感染市场预计将在 2022-2029 年的预测期内实现市场增长。Data Bridge Market Research 分析称，在上述预测期内，市场复合年增长率将达到 5.89%。预计推动这一市场发展的主要因素是人们对该疾病和治疗的认识提高，这有望满足未来的需求。
乙肝病毒（HBV）可引起严重感染，影响肝脏并导致肝病，如肝硬化或肝癌。这些感染无法在早期发现，几周后才会显现出来。这种疾病从出生开始就可能出现，主要由医疗环境中的输血、透析和共用剃须刀引起。乙肝疫苗含有乙肝表面抗原 (HBsAg) 以及病毒包膜蛋白。它也是由酵母细胞制成的。用药疗程包括两到三次注射，间隔两到三个月。免疫系统记忆也有助于抵抗病毒。
在许多资源受限的环境中，乙肝治疗和诊断的机会有限，以及乙肝感染率的上升，预计将在预测期内推动全球乙肝治疗市场的发展。提高认识和负担能力是提高患者在患上晚期肝病之前的诊断率的两个关键因素。此外，提高认识和开发出疗效更高的新型药物，预计将为全球乙肝疫苗市场提供良好的机会。
治疗乙肝病毒的药物和疫苗的开发加速了该市场的增长。艾滋病患者除了使用免疫抑制剂外，还需使用血液透析进行治疗，这将在预测期内推动市场的发展。
然而，高成本和人们不愿意接种任何疫苗等因素限制了全球乙肝疫苗市场的发展。全球乙肝感染市场面临的主要挑战之一是疫苗覆盖率不足。
本乙肝感染市场报告详细介绍了最新发展、贸易法规、进出口分析、生产分析、价值链优化、市场份额、国内和本地市场参与者的影响，分析了新兴收入领域的机会、市场法规的变化、战略市场增长分析、市场规模、类别市场增长、应用领域和主导地位、产品批准、产品发布、地域扩展、市场技术创新。如需了解有关乙肝感染市场的更多信息，请联系 Data Bridge Market Research 获取分析师简报，我们的团队将帮助您做出明智的市场决策，实现市场增长。
全球乙型肝炎感染市场范围和市场规模
乙肝感染市场根据类型、治疗和分销渠道进行细分。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略，并确定您的核心应用领域和目标市场的差异。
- 根据类型，乙型肝炎感染市场分为急性和慢性。
- 根据治疗方式，乙肝感染市场分为抗病毒药物、疫苗、免疫调节药物和手术。抗病毒药物细分市场进一步细分为替比夫定、恩替卡韦、替诺福韦酯、拉米夫定等。免疫调节药物细分市场进一步细分为聚乙二醇干扰素和干扰素α。
- 乙肝感染市场还根据分销渠道细分为医院、零售药店和网上药店。
乙肝感染市场国家层面分析
对乙肝感染市场进行了分析，并按上述国家、类型、治疗方法和分销渠道提供了市场规模信息。
乙型肝炎感染市场报告涉及的国家 包括美国、加拿大、墨西哥、巴西、阿根廷、秘鲁、南美洲其他地区、德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、匈牙利、立陶宛、奥地利、爱尔兰、挪威、波兰、欧洲其他地区、中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、越南、亚太其他地区、沙特阿拉伯、阿联酋、埃及、以色列、科威特、南非、中东和非洲其他地区。
由于乙肝感染病例的增加以及医疗设施的增加，北美在乙肝感染市场占据主导地位，而由于主要公司的大量投资，预计亚太地区在预测期内将以最快的速度增长。
报告的国家部分还提供了影响单个市场因素和国内市场法规变化，这些变化影响了市场的当前和未来趋势。新销售、替代销售、国家人口统计、疾病流行病学和进出口关税等数据点是用于预测单个国家市场情景的一些主要指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、销售渠道的影响。
患者流行病学分析
乙肝感染市场还为您提供详细的市场分析，包括患者分析、预后和治疗。患病率、发病率、死亡率、依从率是报告中提供的一些数据变量。分析流行病学对市场增长的直接或间接影响，以创建更稳健、更全面的多元统计模型，用于预测增长期的市场。
竞争格局和全球乙型肝炎感染市场份额分析
乙肝感染市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、公司优势和劣势、产品发布、临床试验渠道、产品批准、专利、产品宽度和广度、应用优势、技术生命线曲线。以上提供的数据点仅与公司对乙肝感染市场研究的关注有关。
乙型肝炎感染市场的一些主要参与者包括 Apotex Inc、Accord Healthcare、Arbutus Biopharma、Aurobindo Pharma、Arrowhead Pharmaceuticals, Inc.、Bristol-Myers Squibb Company、GlaxoSmithKline plc、Gilead Sciences, Inc.、Lupin Pharmaceuticals, Inc.、Par Pharmaceutical、Merck Sharp and Dohme Corp.、Teva Pharmaceutical Industries Ltd. 和 Zydus Pharmaceuticals, Inc. The Vitec Group plc、FUJIFILM Wako Pure Chemical Corporation、Novartis AG、Teva Pharmaceutical Industries Ltd.、LGM Pharma.、Lannett、NorthStar Rx LLC 和 Par Pharmaceutical 等。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL HEPATITIS B INFECTION MARKET
1.4 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 THERAPEUTICS LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 PESTAL ANALYSIS
4.2 PORTER FIVE FORCES
5 GLOBAL HEPATITIS B INFECTION MARKET: REGULATIONS
5.1 REGULATORY AUTHORITIES IN THE ASIA-PACIFIC REGION
5.2 NORTH AMERICA REGULATORY SCENARIO
5.3 EUROPE REGULATORY SCENARIO
5.4 MIDDLE EAST AND AFRICA REGULATORY SCENARIO
5.5 SOUTH AMERICA REGULATORY SCENARIO
6 PIPELINE ANALYSIS
7 EPIDEMILIOGY
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 INCREASING PREVALENCE OF HEPATITIS B INFECTIONS
8.1.2 TECHNOLOGICAL ADVANCEMENTS IN DIAGNOSTICS
8.1.3 DEVELOPMENT OF COMBINATION THERAPIES FOR HEPATITIS B
8.1.4 STRATEGIC INITIATIVES BY COMPANIES FOR HEPATITIS B INFECTION
8.2 RESTRAINTS
8.2.1 SIDE EFFECTS AND DRUG RESISTANCE
8.2.2 INSUFFICIENT VACCINE COVERAGE FOR HEPATITIS B INFECTION
8.3 OPPORTUNITY
8.3.1 RISING NEW DRUG RELEASES AND INCREASING NEW DRUG PERMITS FOR HEPATITIS B
8.3.2 GOVERNMENT PROGRAMS TO RAISE AWARENESS OF HEPATITIS B INFECTION
8.3.3 ADVANCED RESEARCH AND DEVELOPMENT FOR CLINICAL TRIALS
8.4 CHALLENGES
8.4.1 THE COST OF HEPATITIS B TREATMENTS IS HIGH
8.4.2 STRINGENT REGULATORY POLICIES AND REGIONAL DISPARITIES IN TREATMENT ACCESS
9 GLOBAL HEPATITIS B INFECTION MARKET, BY TYPE
9.1 OVERVIEW
9.2 CHRONIC
9.3 ACUTE
10 GLOBAL HEPATITIS B INFECTION MARKET, BY TREATMENT
10.1 OVERVIEW
10.2 VACCINE
10.2.1 HOSPITAL PHARMACIES
10.2.2 DRUGS STORES AND RETAIL PHARMACIES
10.2.3 ONLINE PHARMACIES
10.3 ANTIVIRAL DRUGS
10.3.1 TENOFOVIR ALAFENAMIDE FUMARATE (TAF)
10.3.2 TENOFOVIR DISOPROXIL FUMARATE (TDF)
10.3.3 ENTECAVIR
10.3.4 OTHERS
10.4 IMMUNE MODULATOR DRUGS
10.4.1 PEGYLATED INTERFERON
10.4.2 INTERFERON ALPHA
10.5 SURGERY
11 GLOBAL HEPATITIS B INFECTION MARKET, BY REGION
11.1 OVERVIEW
11.2 NORTH AMERICA
11.2.1 U.S
11.2.2 CANADA
11.2.3 MEXICO
11.3 SOUTH AMERICA
11.3.1 BRAZIL
11.3.2 ARGENTINA
11.3.3 REST OF SOUTH AMERICA
11.4 MIDDLE EAST AND AFRICA
11.4.1 SOUTH AFRICA
11.4.2 SAUDI ARABIA
11.4.3 EGYPT
11.4.4 KUWAIT
11.4.5 QATAR
11.4.6 U.A.E
11.4.7 OMAN
11.4.8 BAHRAIN
11.4.9 REST OF MIDDLE EAST AND AFRICA
11.5 ASIA-PACIFIC
11.5.1 CHINA
11.5.2 INDIA
11.5.3 INDONESIA
11.5.4 JAPAN
11.5.5 VIETNAM
11.5.6 PHILIPPINES
11.5.7 THAILAND
11.5.8 SOUTH KOREA
11.5.9 AUSTRALIA
11.5.10 SINGAPORE
11.5.11 MALAYSIA
11.5.12 NEW ZEALAND
11.5.13 TAIWAN
11.5.14 REST OF ASIA-PACIFIC
11.6 EUROPE
11.6.1 GERMANY
11.6.2 U.K
11.6.3 TURKEY
11.6.4 RUSSIA
11.6.5 SPAIN
11.6.6 ITALY
11.6.7 SWEDEN
11.6.8 BELGIUM
11.6.9 POLAND
11.6.10 FRANCE
11.6.11 SWITZERLAND
11.6.12 NETHERLANDS
11.6.13 NORWAY
11.6.14 DENMARK
11.6.15 FINLAND
11.6.16 REST OF EUROPE
12 GLOBAL HEPATITIS B TREATMENT MARKET: COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: GLOBAL
12.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
12.3 COMPANY SHARE ANALYSIS: EUROPE
12.4 COMPANY SHARE ANALYSIS: ASIA - PACIFIC
13 SWOT ANALYSIS
14 COMPANY PROFILE
14.1 GILEAD SCIENCES, INC.
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 COMPANY SHARE ANALYSIS
14.1.4 PRODUCT PORTFOLIO
14.1.5 RECENT DEVELOPMENT
14.2 GLAXOSMITHKLINE PLC
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 COMPANY SHARE ANALYSIS
14.2.4 PRODUCT PORTFOLIO
14.2.5 RECENT DEVELOPMENT
14.3 DYNAVAX TECHNOLOGIES CORPORATION
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 COMPANY SHARE ANALYSIS
14.3.4 PRODUCT PORTFOLIO
14.3.5 RECENT DEVELOPMENTS
14.4 F. HOFFMAN-LA ROCHE LTD.
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 COMPANY SHARE ANALYSIS
14.4.4 PRODUCT PORTFOLIO
14.4.5 RECENT DEVELOPMENTS
14.5 BRISTOL-MYERS SQUIBB COMPANY
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 COMPANY SHARE ANALYSIS
14.5.4 PRODUCT PORTFOLIO
14.5.5 RECENT DEVELOPMENTS
14.6 ARROWHEAD PHARMACEUTICALS, INC.
14.6.1 COMPANY SNAPSHOT
14.6.2 REVENUE ANALYSIS
14.6.3 PRODUCT PORTFOLIO
14.6.4 RECENT DEVELOPMENTS
14.7 ARBUTUS BIOPHARMA
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT UPDATES
14.8 AUROBINDO PHARMA
14.8.1 COMPANY SNAPSHOT
14.8.2 REVENUE ANALYSIS
14.8.3 PRODUCT PORTFOLIO
14.8.4 RECENT UPDATES
14.9 LUPIN PHARMACEUTICALS, INC.
14.9.1 COMPANY SNAPSHOT
14.9.2 PRODUCT PORTFOLIO
14.9.3 RECENT UPDATES
14.1 MERCK & CO., INC.,
14.10.1 COMPANY SNAPSHOT
14.10.2 REVENUE ANALYSIS
14.10.3 PRODUCT PORTFOLIO
14.10.4 RECENT DEVELOPMENTS
14.11 NOVARTIS AG
14.11.1 COMPANY SNAPSHOT
14.11.2 REVENUE
14.11.3 PRODUCT PORTFOLIO
14.11.4 RECENT DEVELOPMENT
14.12 TEVA PHARMACEUTICAL INDUSTRIES
14.12.1 COMPANY SNAPSHOT
14.12.2 PRODUCT PORTFOLIO
14.12.3 RECENT DEVELOPMENTS
14.13 ZYDUS PHARMACEUTICALS, INC.
14.13.1 COMPANY SNAPSHOT
14.13.2 PRODUCT PORTFOLIO
14.13.3 REVENUE
14.13.4 RECENT DEVELOPMENT
15 QUESTIONNAIRE
16 RELATED REPORTS
表格列表
TABLE 1 GLOBAL CLINICAL TRIAL AND PIPELINE A-LYSIS AS PER THE COMPANY
TABLE 2 DISTRIBUTION OF PRODUCTS OR PROJECTS BY PHASE
TABLE 3 COUNTRY WISE EPIDEMIOLOGY FOR HEPATITIS B
TABLE 4 COST OF HEPATITIS B MEDICATIONS: BRAND VS. GENERIC PRICES
TABLE 5 GLOBAL HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 6 GLOBAL CHRONIC IN HEPATITIS B INFECTION MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 7 GLOBAL ACUTE IN HEPATITIS B INFECTION MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 8 GLOBAL HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 9 GLOBAL VACCINE IN HEPATITIS B INFECTION MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 10 GLOBAL VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 11 GLOBAL ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 12 GLOBAL ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 13 GLOBAL IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 14 GLOBAL IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 15 GLOBAL SURGERY IN HEPATITIS B INFECTION MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 16 GLOBAL HEPATITIS B INFECTION MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 17 NORTH AMERICA HEPATITIS B INFECTION MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 18 NORTH AMERICA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 19 NORTH AMERICA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 20 NORTH AMERICA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 21 NORTH AMERICA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 22 NORTH AMERICA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 23 U.S. HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 24 U.S. HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 25 U.S. ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 26 U.S. IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 27 U.S. VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 28 CANADA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 29 CANADA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 30 CANADA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 31 CANADA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 32 CANADA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 33 MEXICO HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 34 MEXICO HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 35 MEXICO ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 36 MEXICO IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 37 MEXICO VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 38 SOUTH AMERICA HEPATITIS B INFECTION MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 39 SOUTH AMERICA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 40 SOUTH AMERICA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 41 SOUTH AMERICA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 42 SOUTH AMERICA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 43 SOUTH AMERICA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 44 BRAZIL HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 45 BRAZIL HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 46 BRAZIL ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 47 BRAZIL IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 48 BRAZIL VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 49 ARGENTINA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 50 ARGENTINA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 51 ARGENTINA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 52 ARGENTINA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 53 ARGENTINA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 54 REST OF SOUTH AMERICA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 55 MIDDLE EAST AND AFRICA HEPATITIS B INFECTION MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 56 MIDDLE EAST AND AFRICA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 57 MIDDLE EAST AND AFRICA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 58 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 59 MIDDLE EAST AND AFRICA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 60 MIDDLE EAST AND AFRICA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 61 SOUTH AFRICA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 62 SOUTH AFRICA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 63 SOUTH AFRICA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 64 SOUTH AFRICA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 65 SOUTH AFRICA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 66 SAUDI ARABIA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 67 SAUDI ARABIA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 68 SAUDI ARABIA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 69 SAUDI ARABIA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 70 SAUDI ARABIA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 71 EGYPT HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 72 EGYPT HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 73 EGYPT ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 74 EGYPT IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 75 EGYPT VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 76 KUWAIT HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 77 KUWAIT HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 78 KUWAIT ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 79 KUWAIT IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 80 KUWAIT VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 81 QATAR HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 82 QATAR HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 83 QATAR ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 84 QATAR IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 85 QATAR VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 86 U.A.E HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 87 U.A.E HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 88 U.A.E ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 89 U.A.E IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 90 U.A.E VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 91 OMAN HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 92 OMAN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 93 OMAN ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 94 OMAN IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 95 OMAN VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 96 BAHRAIN HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 97 BAHRAIN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 98 BAHRAIN ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 99 BAHRAIN IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 100 BAHRAIN VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 101 REST OF MIDDLE EAST AND AFRICA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 102 ASIA-PACIFIC HEPATITIS B INFECTION MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 103 ASIA-PACIFIC HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 104 ASIA-PACIFIC HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 105 ASIA-PACIFIC ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 106 ASIA-PACIFIC IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 107 CHINA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 108 CHINA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 109 CHINA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 110 CHINA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 111 CHINA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 112 CHINA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 113 INDIA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 114 INDIA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 115 INDIA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 116 INDIA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 117 INDIA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 118 INDONESIA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 119 INDONESIA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 120 INDONESIA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 121 INDONESIA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 122 INDONESIA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 123 JAPAN HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 124 JAPAN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 125 JAPAN ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 126 JAPAN IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 127 JAPAN VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 128 VIETNAM HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 129 VIETNAM HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 130 VIETNAM ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 131 VIETNAM IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 132 VIETNAM VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 133 PHILIPPINES HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 134 PHILIPPINES HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 135 PHILIPPINES ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 136 PHILIPPINES IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 137 PHILIPPINES VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 138 THAILAND HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 139 THAILAND HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 140 THAILAND ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 141 THAILAND IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 142 THAILAND VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 143 SOUTH KOREA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 144 SOUTH KOREA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 145 SOUTH KOREA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 146 SOUTH KOREA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 147 SOUTH KOREA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 148 AUSTRALIA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 149 AUSTRALIA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 150 AUSTRALIA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 151 AUSTRALIA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 152 AUSTRALIA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 153 SINGAPORE HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 154 SINGAPORE HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 155 SINGAPORE ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 156 SINGAPORE IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 157 SINGAPORE VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 158 MALAYSIA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 159 MALAYSIA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 160 MALAYSIA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 161 MALAYSIA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 162 MALAYSIA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 163 NEW ZEALAND HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 164 NEW ZEALAND HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 165 NEW ZEALAND ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 166 NEW ZEALAND IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 167 NEW ZEALAND VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 168 TAIWAN HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 169 TAIWAN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 170 TAIWAN ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 171 TAIWAN IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 172 TAIWAN VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 173 REST OF ASIA-PACIFIC HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 174 EUROPE HEPATITIS B INFECTION MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 175 EUROPE HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 176 EUROPE HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 177 EUROPE ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 178 EUROPE IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 179 EUROPE VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 180 GERMANY HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 181 GERMANY HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 182 GERMANY ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 183 GERMANY IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 184 GERMANY VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 185 U.K. HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 186 U.K. HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 187 U.K. ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 188 U.K. IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 189 U.K. IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 190 TURKEY HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 191 TURKEY HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 192 TURKEY ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 193 TURKEY IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 194 TURKEY VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 195 RUSSIA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 196 RUSSIA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 197 RUSSIA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 198 RUSSIA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 199 RUSSIA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 200 SPAIN HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 201 SPAIN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 202 SPAIN ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 203 SPAIN IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 204 SPAIN VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 205 ITALY HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 206 ITALY HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 207 ITALY ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 208 ITALY IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 209 ITALY VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 210 SWEDEN HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 211 SWEDEN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 212 SWEDEN ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 213 SWEDEN IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 214 SWEDEN VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 215 BELGIUM HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 216 BELGIUM HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 217 BELGIUM ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 218 BELGIUM IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 219 BELGIUM VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 220 POLAND HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 221 POLAND HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 222 POLAND ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 223 POLAND IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 224 POLAND VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 225 FRANCE HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 226 FRANCE HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 227 FRANCE ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 228 FRANCE IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 229 FRANCE VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 230 SWITZERLAND HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 231 SWITZERLAND HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 232 SWITZERLAND ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 233 SWITZERLAND IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 234 SWITZERLAND VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 235 NETHERLANDS HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 236 NETHERLANDS HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 237 NETHERLANDS ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 238 NETHERLANDS IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 239 NETHERLANDS VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 240 NORWAY HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 241 NORWAY HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 242 NORWAY HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 243 NORWAY IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 244 NORWAY VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 245 DENMARK HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 246 DENMARK HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 247 DENMARK ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 248 DENMARK IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 249 DENMARK VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 250 FINLAND HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 251 FINLAND HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 252 FINLAND ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 253 FINLAND IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 254 FINLAND VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 255 REST OF EUROPE HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
图片列表
FIGURE 1 GLOBAL HEPATITIS B INFECTION MARKET: SEGMENTATION
FIGURE 2 GLOBAL HEPATITIS B INFECTION MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL HEPATITIS B INFECTION MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL HEPATITIS B INFECTION MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL HEPATITIS B INFECTION MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL HEPATITIS B INFECTION MARKET: MULTIVARIATE MODELLING
FIGURE 7 GLOBAL HEPATITIS B INFECTION MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 GLOBAL HEPATITIS B INFECTION MARKET: DBMR MARKET POSITION GRID
FIGURE 9 GLOBAL HEPATITIS B INFECTION MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 GLOBAL HEPATITIS B INFECTION MARKET: SEGMENTATION
FIGURE 11 ASIA PACIFIC IS EXPECTED TO DOMINATE THE GLOBAL HEPATITIS B INFECTION MARKET AND IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2024 TO 2031
FIGURE 12 TWO SEGMENTS COMPRISE THE GLOBAL HEPATITIS B INFECTION MARKET, BY TYPE
FIGURE 13 EXECUTIVE SUMMARY
FIGURE 14 STRATEGIC DECISIONS
FIGURE 15 GLOBAL HEPATITIS B INFECTION MARKET
FIGURE 16 CHRONIC SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL HEPATITIS B INFECTION MARKET IN 2024 & 2031
FIGURE 17 ASIA PACIFIC IS THE FASTEST GROWING MARKET FOR THE GLOBAL HEPATITIS B INFECTION MARKET IN 2024 & 2031
FIGURE 18 DROC ANALYSIS
FIGURE 19 BURDEN OF HBV INFECTION IN THE GENERAL POPULATION BY WHO REGION, 2019
FIGURE 20 GLOBAL HEPATITIS B INFECTION MARKET: BY TYPE, 2023
FIGURE 21 GLOBAL HEPATITIS B INFECTION MARKET: BY TYPE, 2024-2031 (USD MILLION)
FIGURE 22 GLOBAL HEPATITIS B INFECTION MARKET: BY TYPE, CAGR (2024-2031)
FIGURE 23 GLOBAL HEPATITIS B INFECTION MARKET: BY TYPE, LIFELINE CURVE
FIGURE 24 GLOBAL HEPATITIS B INFECTION MARKET: BY TREATMENT, 2023
FIGURE 25 GLOBAL HEPATITIS B INFECTION MARKET: BY TREATMENT, 2024-2031 (USD MILLION)
FIGURE 26 GLOBAL HEPATITIS B INFECTION MARKET: BY TREATMENT, CAGR (2024-2031)
FIGURE 27 GLOBAL HEPATITIS B INFECTION MARKET BY TREATMENT, LIFELINE CURVE
FIGURE 28 GLOBAL HEPATITIS B INFECTION MARKET, SNAPSHOT
FIGURE 29 GLOBAL HEPATITIS B TREATMENT MARKET: COMPANY SHARE 2023 (%)
FIGURE 30 NORTH AMERICA HEPATITIS B TREATMENT MARKET: COMPANY SHARE 2023 (%)
FIGURE 31 EUROPE HEPATITIS B TREATMENT MARKET: COMPANY SHARE 2023 (%)
FIGURE 32 ASIA-PACIFIC HEPATITIS B TREATMENT MARKET: COMPANY SHARE 2023 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
